The role of neoadjuvant therapy in surgically resectable esophageal cancer - PubMed (original) (raw)
The role of neoadjuvant therapy in surgically resectable esophageal cancer
S G Swisher et al. Arch Surg. 1996 Aug.
Abstract
Objective: To determine the effect of neoadjuvant therapy (NT) (preoperative chemotherapy, radiation therapy, or both) in surgically resectable esophageal cancer.
Design: A retrospective review over a 20-year period.
Setting: A tertiary academic medical center.
Participants: All patients undergoing surgical resection for esophageal cancer (N = 316) over this time period.
Main outcome measures: Perioperative morbidity and mortality, local and distant recurrences, and overall survival.
Results: Patients undergoing NT (n = 106) had prognostic factors similar to those treated with surgery alone (n = 210). No increase was noted in surgical morbidity with NT (anastomotic leaks, reoperation rates, complications, or extended hospital stays). Overall survival was not improved by NT (median survival, 14 months) except in the subset of patients (11/83) who responded completely (100% histological necrosis) to preoperative chemotherapy (median survival, 79.2 months; P < .02). Complete response to radiation therapy alone was not associated with improved survival. Partial necrosis of the primary tumor was seen in 13 (15%) of 83 patients but conferred no survival advantage. Complete response to preoperative chemotherapy was associated with squamous cell pathological features and excellent performance status as measured by preanesthesia evaluation.
Conclusions: The addition of NT did not increase perioperative morbidity or mortality. Only the subset of patients who had a complete response to preoperative chemotherapy showed a survival advantage. Excellent performance status and squamous cell pathological features were associated with an increased chance of complete pathological response following preoperative chemotherapy.
Similar articles
- Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer.
Luu TD, Gaur P, Force SD, Staley CA, Mansour KA, Miller JI Jr, Miller DL. Luu TD, et al. Ann Thorac Surg. 2008 Apr;85(4):1217-23; discussion 1223-4. doi: 10.1016/j.athoracsur.2007.11.070. Ann Thorac Surg. 2008. PMID: 18355499 - A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer.
Urschel JD, Vasan H, Blewett CJ. Urschel JD, et al. Am J Surg. 2002 Mar;183(3):274-9. doi: 10.1016/s0002-9610(02)00795-x. Am J Surg. 2002. PMID: 11943125 - Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J Jr, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R. Jin J, et al. Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):427-36. doi: 10.1016/j.ijrobp.2004.03.033. Int J Radiat Oncol Biol Phys. 2004. PMID: 15380576 - Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma.
Mariette C, Taillier G, Van Seuningen I, Triboulet JP. Mariette C, et al. Ann Thorac Surg. 2004 Oct;78(4):1177-83. doi: 10.1016/j.athoracsur.2004.02.068. Ann Thorac Surg. 2004. PMID: 15464466 Review. - Neoadjuvant chemoradiotherapy for esophageal cancer: is it worthwhile?
Tamim WZ, Davidson RS, Quinlan RM, O'Shea MA, Orr RK, Swanson RS. Tamim WZ, et al. Arch Surg. 1998 Jul;133(7):722-6. doi: 10.1001/archsurg.133.7.722. Arch Surg. 1998. PMID: 9687999 Review.
Cited by
- Analysis of postoperative complications after esophagectomy for esophageal cancer in patients receiving neoadjuvant therapy.
Eguchi R, Ide H, Nakamura T, Hayashi K, Ohta M, Okamoto F, Itoh H, Takasaki K. Eguchi R, et al. Jpn J Thorac Cardiovasc Surg. 1999 Nov;47(11):552-8. doi: 10.1007/BF03218061. Jpn J Thorac Cardiovasc Surg. 1999. PMID: 10614095 - Gastroesophageal junction adenocarcinoma.
Swisher SG, Pisters PW, Komaki R, Lahoti S, Ajani JA. Swisher SG, et al. Curr Treat Options Oncol. 2000 Dec;1(5):387-98. doi: 10.1007/s11864-000-0066-1. Curr Treat Options Oncol. 2000. PMID: 12057146 Review. - Serial endoscopic ultrasound in the assessment of response to chemoradiotherapy for carcinoma of the esophagus.
Bowrey DJ, Clark GW, Roberts SA, Hawthorne AB, Maughan TS, Williams GT, Carey PD. Bowrey DJ, et al. J Gastrointest Surg. 1999 Sep-Oct;3(5):462-7. doi: 10.1016/s1091-255x(99)80098-5. J Gastrointest Surg. 1999. PMID: 10482701 Clinical Trial. - Neoadjuvant chemoradiotherapy for esophageal cancer using weekly Paclitaxel and Carboplatin plus infusional 5-Fluorouracil.
Gannett DE, Wolf RF, Takahashi GW, Louie J, Wagner RC, Ey FS, Owens MM, Johnson WE, Cook DW, Alberty RE. Gannett DE, et al. Gastrointest Cancer Res. 2007 Jul;1(4):132-8. Gastrointest Cancer Res. 2007. PMID: 19262701 Free PMC article. - Quality of complication reporting in the surgical literature.
Martin RC 2nd, Brennan MF, Jaques DP. Martin RC 2nd, et al. Ann Surg. 2002 Jun;235(6):803-13. doi: 10.1097/00000658-200206000-00007. Ann Surg. 2002. PMID: 12035036 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials